Effective management of a diabetic patient with hormone-receptor-positive, HER2‑negative metastatic breast cancer using nanosomal docetaxel lipid suspension for 12 cycles: A case report

The present study reports a case of a 40-year-old diabetic female patient diagnosed with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) in July 2017 and admitted to Cancure Cancer Centre (Tiruchirappalli, India). Following initial surgery and adjuvant treatment with four cycles each of fluorouracil, doxorubicin, and Cyclophosphamide chemotherapy and paclitaxel, radiotherapy and tamoxifen, the patient developed multiple metastases to the liver, lung and bones 3 years later. Palliative treatment with nanosomal docetaxel lipid suspension (NDLS) was started, resulting in a partial response (PR) after six cycles. NDLS was continued for 12 cycles in total, with good tolerance and no serious adverse effects. The patient maintained a PR and was managed with maintenance leuprolide, letrozole and palbociclib. The patient developed disease progression and died in July 2024, leading to a progression-free survival of ~ two years and an overall survival of two years and six months. To the best of our knowledge, the present case is among the first to report the safety and efficacy of 12 cycles of NDLS in MBC.